AU2020276703A1 - Treatment of TLR-4 mediated diseases and conditions with aptamers targeting TLR-4 - Google Patents

Treatment of TLR-4 mediated diseases and conditions with aptamers targeting TLR-4 Download PDF

Info

Publication number
AU2020276703A1
AU2020276703A1 AU2020276703A AU2020276703A AU2020276703A1 AU 2020276703 A1 AU2020276703 A1 AU 2020276703A1 AU 2020276703 A AU2020276703 A AU 2020276703A AU 2020276703 A AU2020276703 A AU 2020276703A AU 2020276703 A1 AU2020276703 A1 AU 2020276703A1
Authority
AU
Australia
Prior art keywords
aptamer
tlr
aptoll
present disclosure
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020276703A
Other languages
English (en)
Inventor
Lisardo BOSCÁ GOMAR
Fernando De Castro Soubriet
Beatriz FERNANDEZ GÓMEZ
Macarena HERNÁNDEZ JIMÉNEZ
Ignacio LIZASOAIN HERNÁNDEZ
María Ángeles MORO SÁNCHEZ
David PIÑEIRO DEL RIO
Diego Pérez Rodríguez
David SEGARRA DE LA PEÑA
María Eugenia ZARABOZO LEAL
Carlos ZARAGOZA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2020276703A1 publication Critical patent/AU2020276703A1/en
Assigned to MERCK PATENT GMBH reassignment MERCK PATENT GMBH Request for Assignment Assignors: APTATARGETS, S.L.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2020276703A 2019-05-16 2020-05-16 Treatment of TLR-4 mediated diseases and conditions with aptamers targeting TLR-4 Pending AU2020276703A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962849068P 2019-05-16 2019-05-16
US201962849072P 2019-05-16 2019-05-16
US62/849,068 2019-05-16
US62/849,072 2019-05-16
EP19382425 2019-05-27
EP19382424 2019-05-27
EP19382425 2019-05-27
EP19382424 2019-05-27
PCT/IB2020/054655 WO2020230109A1 (en) 2019-05-16 2020-05-16 Treatment of tlr-4 mediated diseases and conditions with aptamers targeting tlr-4

Publications (1)

Publication Number Publication Date
AU2020276703A1 true AU2020276703A1 (en) 2021-12-09

Family

ID=73288968

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020276703A Pending AU2020276703A1 (en) 2019-05-16 2020-05-16 Treatment of TLR-4 mediated diseases and conditions with aptamers targeting TLR-4

Country Status (7)

Country Link
US (2) US20220233572A1 (https=)
EP (1) EP3969011A1 (https=)
JP (2) JP7789563B2 (https=)
CN (1) CN113966220A (https=)
AU (1) AU2020276703A1 (https=)
CA (2) CA3140285A1 (https=)
WO (2) WO2020230109A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12390172B2 (en) * 2021-02-19 2025-08-19 Canon Medical Systems Corporation Method and apparatus for displaying medical images
WO2024064288A1 (en) * 2022-09-22 2024-03-28 Thomas Jefferson University Tlr4 inhibitors for cancer treatment
IL321911A (en) 2023-01-05 2025-09-01 Merck Patent Gmbh Aptol molecules for the treatment of ischemic stroke and intracranial hemorrhages
AU2024275027A1 (en) 2023-05-22 2025-12-11 Merck Patent Gmbh New tlr-4 antagonist aptamers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPH088933B2 (ja) * 1987-07-10 1996-01-31 日本ゼオン株式会社 カテ−テル
SG10201406016SA (en) 2006-04-03 2014-11-27 Stella Aps Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
EP2619189B1 (en) 2010-09-24 2020-04-15 Zoetis Services LLC Isoxazoline oximes as antiparasitic agents
ES2555160B1 (es) 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos
WO2020069313A2 (en) * 2018-09-28 2020-04-02 Henry Ford Health System Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke

Also Published As

Publication number Publication date
JP7789563B2 (ja) 2025-12-22
JP2022533966A (ja) 2022-07-27
WO2020230108A1 (en) 2020-11-19
CN113966220A (zh) 2022-01-21
US20220233572A1 (en) 2022-07-28
CA3291318A1 (en) 2026-03-02
CA3140285A1 (en) 2020-11-19
JP2025148491A (ja) 2025-10-07
EP3969011A1 (en) 2022-03-23
US20220233570A1 (en) 2022-07-28
WO2020230109A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
JP7789563B2 (ja) Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療
JP7398007B2 (ja) Ａｎｇｐｔｌ３発現を阻害する組成物及び方法
JP2020062023A (ja) 呼吸器疾患関連遺伝子特異的ｓｉＲＮＡ、そのようなｓｉＲＮＡを含む二重らせんオリゴＲＮＡ構造体およびこれを含む呼吸器疾患予防または治療用組成物
CN104145018B (zh) 新型C5a结合性核酸
PT2596807E (pt) Aptâmeros de ligação ao complemento e agentes anti-c5 úteis no tratamento de distúrbios oculares
JP2024056830A (ja) Ｆｘｉの発現を低下させるための化合物及び方法
WO2022121959A1 (zh) siRNA分子及其在治疗冠状动脉疾病中的应用
JP2025516306A (ja) 中枢神経系送達用の脂質ナノ粒子製剤
JP2025163035A (ja) 筋再生および筋成長
US20240279667A1 (en) Compositions and methods of treating diseases associated with bile acid transporter
US12458657B2 (en) Neurogenesis
US20210292768A1 (en) Compositions and agents against nonalcoholic steatohepatitis
TW202540420A (zh) 用於抑制LPA的基因表現的siRNA，含其的組合物及其用途
TW202220675A (zh) 降低ｚ－ａａｔ蛋白水準之方法
JP7535315B2 (ja) Ｈｉｃ－５インヒビターの新規用途
TW202330920A (zh) 用於調節ａｐｏｃ３表現之組合物及方法
WO2025252223A1 (zh) 一种抑制PCSK9基因表达的RNAi制剂及其应用
WO2026061490A1 (zh) 用于抑制FXII基因表达的siRNA及其缀合物和用途
JP2025512445A (ja) Ｓｃａｐ活性を調節するための組成物及び方法
CN118922540A9 (zh) 前激肽释放酶调节组合物及其使用方法
JP2024537874A (ja) Ａｄａｍｔｓ１４阻害
WO2025231388A1 (en) Methods and compositions for treating pompe disease
CN119654413A (zh) Itfg1抑制性核酸
TW202546228A (zh) 用於抑制胰島素樣生長因子１受體表達的ｒｎａ抑制劑
HK40115827A (zh) 用於抑制ldha表达的方法和组合物

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MERCK PATENT GMBH

Free format text: FORMER APPLICANT(S): APTATARGETS, S.L.